Clinical Trial Update: Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous DNase to reduce systemic inflammation after ischemic stroke.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Response
• Stroke

Drugs mentioned

• DNase

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Ischemic Stroke, Inflammatory Response | Phase 2 | Status: UNKNOWN